Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP33
- Development stage
- Preclinical
- Lead developer
- Aurobindo Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BP33 is a biosimilar monoclonal antibody currently under development by CuraTeQ Biologics, a subsidiary of Aurobindo Pharma. The drug is being developed for indications within the field of haematology. As a biosimilar, BP33 is designed to be highly similar to an existing, approved reference biologic medication in terms of safety, purity, and potency. However, the specific reference product and the molecular target of BP33 have not yet been publicly disclosed by the developer. The project is part of Aurobindo's expanding biosimilar pipeline aimed at providing more affordable versions of complex biological therapies.
Beyond the preview
Go deeper on BP33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP33.